On Monday, Shares of CytRx Corporation (NASDAQ:CYTR), surged 19.19% to $4.41.
CytRx Corporation, declared an interim analysis from its two ongoing phase 1b aldoxorubicin combination studies pairing aldoxorubicin with either gemcitabine or ifosfamide. Both studies combine standard doses of gemcitabine or ifosfamide with escalating doses of aldoxorubicin. The combinations appear to be well tolerated, and even at the lowest dose level of aldoxorubicin (170 mg/m2), impressive tumor responses have been observed so far in patients with bone cancer (osteosarcoma) and a variety of soft tissue sarcomas. As such, aldoxorubicin has the potential when used in combination with other cancer agents to become an important new weapon against chemotherapy resistant cancers.
The first study is an open-label, Phase 1b clinical trial investigating the preliminary safety and activity of ascending doses of aldoxorubicin plus ifosfamide/mesna for the first-line treatment of patients with locally advanced, unresectable, and/or metastatic sarcomas, counting bone cancer. Interim results from seven evaluable patients show that the combination of aldoxorubicin plus ifosfamide/mesna was well tolerated. One bone cancer patient achieved a complete tumor response following five treatment cycles. The Company anticipates to complete dose escalation in this trial in the second half of 2015, and to start adding sarcoma patients at the maximum well-tolerated dose combination.
The second trial is an open-label, Phase 1b clinical trial investigating the preliminary safety and activity of ascending doses of aldoxorubicin plus gemcitabine in patients with advanced, unresectable, metastatic solid tumors that have either relapsed or were refractory to treatment following at least one preceding chemotherapy or immunotherapy regimen, and for which no standard approved therapy exists. Interim results from seven patients show that the combination of aldoxorubicin plus gemcitabine was well tolerated. Tumor shrinkage was observed in three of seven patients following two treatment cycles. One patient with advanced dedifferentiated chondrosarcoma (cartilage/bone cancer), chronic severe pain and inability to function normally demonstrated meaningful quality of life improvements, counting stopping prescription narcotic pain medications and returning to full-time work. The Company anticipates to complete dose escalation in this trial in the second half of 2015, and to start adding patients with either relapsed pancreatic or ovarian cancer at the maximum well-tolerated dose combination.
CytRx Corporation operates as a biopharmaceutical research and development company specializing in oncology. The company’s product candidate is aldoxorubicin, which is in Phase III clinical trial as a therapy for patients with soft tissue sarcomas (STS) whose tumors have progressed following treatment with chemotherapy.
At the end of Monday’s trade, Shares of Cloud Peak Energy Inc. (NYSE:CLD), jumped 7.67% to $7.02.
Cloud Peak Energy, declared results for the first quarter of 2015.
- First quarter 2015 Adjusted EBITDA of $39.4 million contrast to $39.3 million for the first quarter of 2014.
- Shipments for the first quarter of 2015 were 19.7 million tons, down slightly as Cordero Rojo Mine transitions to lower production rates.
- Cost per ton was reduced to $10.02 in the first quarter of 2015 from $10.63 in the first quarter of 2014. The cost improvement was primarily due to a decrease of over 40 percent in diesel costs.
- Accessible liquidity of $726.1 million, counting cash and investments of $186.2 million, at March 31, 2015. During the first quarter of 2015, cash flow from operations totaled $31.9 million.
Cloud Peak Energy Inc., through its auxiliaries, produces coal in the Powder River Basin (PRB) and the United States. The company operates through Owned and Operated Mines, Logistics and Related Activities, and Corporate and Other segments. It produces and sells sub-bituminous thermal coal with low sulfur content primarily to electric utilities operating in the United States and internationally.
MEI Pharma, Inc. (NASDAQ:MEIP), ended its last trade with 7.04% gain, and closed at $2.13.
MEI Pharma, declared new pre-clinical data showing mitochondria-specific effects of the Company’s investigational drug candidate ME-344 in cancer cells, counting significantly improved anti-tumor activity when combined with a tyrosine-kinase inhibitor (TKI). In addition, a recently published study found ME-344 to be a potent inhibitor of mitochondrial oxidative phosphorylation (OXPHOS) complex I, a direct molecular target.
“We continue to be very excited by the potential of this novel mitochondrial inhibitor,” said Daniel P. Gold, Ph.D., President and Chief Executive Officer of MEI Pharma. “ME-344 has demonstrated broad and potent anti-tumor activity in a number of pre-clinical studies, followed by promising single-agent activity in the clinic. Now a body of data is emerging that show compelling anti-cancer effects when combining ME-344 with anti-angiogenic agents, such as TKIs, to inhibit both mitochondrial and glycolytic metabolism. These new data will assist to direct future studies of ME-344 as we near completion of our Phase Ib study in small cell lung and ovarian cancers.”
MEI Pharma, Inc., an oncology company, focuses on the clinical development of novel therapies for the treatment of cancer. The company’s lead drug candidate is Pracinostat, an orally accessible histone deacetylase inhibitor, which is in Phase II clinical trial for the treatment of hematologic diseases, such as myelodysplastic syndrome and acute myeloid leukemia.
Finally, The Spectranetics Corporation (NASDAQ:SPNC), closed at $26.01, with 6.91% gain.
The Spectranetics Corporation, declared that its administration will be participating in two forthcoming investor conferences.
Spectranetics administration is planned to present at the 2015 Bank of America Merrill Lynch Healthcare Conference in Las Vegas on Thursday, May 14, 2015 at 10:40 am PT.
The Spectranetics Corporation, together with its auxiliaries, develops, manufactures, markets, and distributes single-use medical devices used in minimally invasive procedures in the cardiovascular system. Its products are used to cross, prepare, and treat arterial blockages in the legs and heart, and to remove pacemaker and defibrillator cardiac leads.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.